Pancreatic cancer drug Afinitor by Novartis AG's has been approved by the U.S. FDA for a rare type of pancreatic cancer that has few treatment options, reports Reuters. The Swiss drugmaker said in a statement, "Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumours (NET) of pancreatic origin."
"This marks the first approval of a treatment for this patient population in the United States in nearly 30 years," they added, Reuters reports.
Pancreatic Cancer Drug Afinitor Approved By FDA
Authorities in France have placed more than a third of the country under a red heat...
An influenza outbreak has reportedly sickened more than 150 recruits in training at Lackland air force...
One morning early last July, Micha Bitsinnie arrived at work to an onslaught of messages from...
